Finerenone attenuates myocardial injury and enhances vascular repair via regulation of autophagy, apoptosis, and angiogenesis Authors: Yebao Wang, Junyi Zhang, Feng Lv, Ting Zhang, Yafeng Zhou Published: 2026 ABSTRACT Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has demonstrated significant efficacy in the management of myocardial infarction (MI). However, its direct cytoprotective effects on cardiomyocytes and vascular endothelial cells remain unclear. This study was performed to evaluate the cardioprotective and vasoprotective effects of finerenone following MI and to elucidate its underlying mechanisms. An in vitro oxygen-glucose deprivation (OGD) model was utilized to mimic ischemic conditions. H9C2 rat cardiomyoblasts and human umbilical vein endothelial cells were employed to assess the protective effects of finerenone. For in vivo assessment, a murine model of MI was established and treated with oral finerenone for 28 consecutive days. Cardioprotective outcomes were evaluated through electrocardiography, echocardiography, serum biochemical markers, histopathological analyses, and protein expression profiling. Finerenone significantly improved the viability of cardiomyocytes and endothelial cells subjected to OGD, reduced autophagosome accumulation by enhancing autophagosome degradation, inhibited apoptosis, and promoted endothelial cell migration and tube formation capacity. In vivo, finerenone improved cardiac function parameters, reduced serum levels of myocardial enzyme profiles and brain natriuretic peptides, decreased myocardial infarct size, enhanced left ventricular function, and alleviated myocardial inflammation, fibrosis and apoptosis. Mechanistically, finerenone downregulated the expression of ATG5 and apoptosis-related molecules in myocardial tissue, while enhancing the expression of Ang and VEGF involved in angiogenesis. Finerenone confers significant cardioprotection by inhibiting autophagy, apoptosis, and enhancing angiogenesis in both cardiomyocytes and vascular endothelial cells. These findings provide experimental evidence for the clinical utility of finerenone for secondary prevention after MI.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-52948-z. Introduction Myocardial infarction (MI) is defined as the irreversible death of cardiomyocytes resulting from sustained myocardial ischemia. Survivors of MI exhibit a significantly increased risk of recurrent cardiovascular events during the post-acute phase, rendering secondary prevention aimed at attenuating myocardial structural remodeling and functional decline a critical focus in clinical management. Rapid reperfusion strategies, including percutaneous coronary intervention (PCI) and thrombolytic therapy, have become the cornerstone of acute MI management, substantially reducing short-term mortality by restoring blood flow to the ischemic myocardium1. However, despite the widespread application of reperfusion therapy, a large proportion of MI survivors still develop adverse cardiac remodeling, heart failure, and recurrent ischemia in the long term2,3. This clinical challenge arises partly from myocardial ischemia-reperfusion (I/R) injury induced by reperfusion itself, as well as the incomplete reversal of subcellular damage and persistent inflammatory responses in the post-ischemic myocardium4,5. Moreover, even with optimal reperfusion, the irreversible loss of cardiomyocytes and subsequent myocardial fibrosis inevitably lead to progressive cardiac dysfunction6, highlighting the urgent need for novel cardioprotective measures that complement reperfusion therapy to improve long-term prognosis. The pathological distinction between MI and typical myocardial injury lies in the presence of ischemic necrosis within cardiomyocytes. Given that cardiomyocytes are terminally differentiated, long-lived cells with limited regenerative capacity, enhancing their survival and functional preservation is a central therapeutic strategy for improving prognosis7. Currently, accumulating evidence suggests that conventional secondary prevention measures, such as antiplatelet therapy, lipid-lowering drugs, and beta-blockers, can only partially mitigate the risk of post-MI adverse events, further underscoring the need to develop new targeted cardioprotective agents8. In recent years, the mineralocorticoid receptor (MR) signaling pathway has emerged as a key regulatory axis in myocardial injury and remodeling, rendering it a promising target for cardioprotective intervention. Existing studies have demonstrated that aberrant activation of MR signaling exacerbates myocardial I/R injury, promotes inflammatory responses and myocardial fibrosis, and accelerates cardiomyocyte apoptosis, all of which contribute to post-MI adverse cardiac remodeling and functional deterioration9–11. Currently, mineralocorticoid receptor antagonists (MRAs) have been extensively employed in mitigating cardiac remodeling12 and treating heart failure13. Finerenone, a novel non-steroidal MRA, demonstrates superior selectivity and affinity for the MR compared to traditional agents such as spironolactone and eplerenone, while exhibiting a more favorable safety profile14,15. Emerging evidence indicates that finerenone exerts multifaceted cardioprotective effects, including anti-inflammatory, anti-fibrotic, anti-apoptotic and antioxidative actions, primarily via antagonism of MR-mediated signaling pathways16. These mechanisms collectively contribute to the attenuation of myocardial fibrosis, improvement of cardiac function, and preservation of coronary vasodilatory capacity, predominantly through modulation of MR activity in vascular smooth muscle cells and myeloid-derived immune populations. Nonetheless, current investigations predominantly focus on finerenone’s protective effects mediated by non-cardiomyocyte cell types. Its direct cytoprotective impact on cardiomyocytes and its influence on vascular endothelial cells remain unclear. Moreover, studies evaluating finerenone monotherapy in conventional MI models are lacking. Therefore, elucidating the integrative cardioprotective roles of finerenone in MI is essential for comprehensively understanding its therapeutic potential and expanding its application in secondary prevention. In the present study, we initially assessed the protective potential of finerenone against oxygen-glucose deprivation (OGD)-induced injury in H9C2 cardiomyoblasts and vascular endothelial cells. Subsequently, by integrating in vitro and in vivo experiments, we focused on autophagy, apoptosis, and angiogenesis, three core pathways involved in MI progression, to explore the cardioprotective effects of finerenone monotherapy and decipher its underlying molecular mechanisms, hoping to provide novel experimental basis for the clinical utility of finerenone in MI secondary prevention. Materials and methods Cell Lines and experimental animals The rat cardiac-derived H9C2 cell line (ACL-0143) and human umbilical vein endothelial cell line (HUVEC, CTCC-124) were acquired from the Chinese Type Culture Collection (CTCC). These cell lines were maintained in high-glucose Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS, Gibco, USA) and maintained at 37 °C in a humidified incubator with 5% CO₂. Male C57BL/6 mice aged 6 to 8 weeks were obtained from Cavens Laboratory Animal Co., Ltd. (Changzhou, China). Animals were housed under controlled environmental conditions, including a temperature of 25 ± 2 °C, relative humidity of 60 ± 5%, and a standard 12-hour light/dark cycle. All mice underwent a one-week acclimatization period before experimental manipulation. Other materials included normal saline, finerenone (MCE HY-111372), pipettes, syringes, analytical balance, surgical instruments, etc. This study was performed in line with the principles of the Declaration of Helsinki. The experimental plan was ethically approved by the Animal Protection and Use Committee of Guangxi Zhuoqiang Biotechnology Co., LTD. Oxygen-glucose deprivation/reperfusion (OGD/R) and drug treatment H9C2 cells were seeded into 6-, 12-, or 96-well plates and cultured for 24 h. Subsequently, the culture medium was then replaced with glucose-free DMEM (G431055, Yuanpei Biotechnology, China). To induce OGD, the plates were transferred to a hypoxia incubator (PH-min, PH Biotechnology, China) maintained at 37 °C and equilibrated with a gas mixture containing 5% CO₂, 90% N₂, and 1% O₂ for 3 h. To mimic reperfusion, the medium was immediately replaced with fresh complete DMEM supplemented with finerenone or vehicle control, and cells were returned to normoxic conditions (21% O₂, 5% CO₂) for an additional 1–6 h. After this treatment, cells were incubated in fresh complete medium under normoxic conditions for further 24 h. Control cells were maintained under normoxic conditions throughout the treatment without exposure to OGD/R. Evaluation of lactate dehydrogenase (LDH) release, cell viability, and apoptosis Cell viability was evaluated using the Cell Counting Kit-8 (CCK-8, M006, PH Biotechnology, China). Optical density (OD) values were measured at 450 nm using a microplate reader (MK3, Thermo, USA). To assess cell membrane integrity and cytotoxicity, LDH release into the culture supernatant was measured. Culture media were collected after centrifugation and transferred to separate 96-well plates. LDH levels was quantified using an LDH assay kit (A020-2-2, Nanjing Jiancheng, China), and absorbance was recorded at 492 nm. H9C2 cells were seeded at a density of 2 × 10⁵ cells per well in 6-well plates. Following OGD/R and finerenone treatment, apoptosis was assessed by flow cytometry using the Annexin V-FITC/PI Apoptosis Detection Kit (401006, BestBio, China) in combination with a FACSVerse cytometer (BD, USA) to determine the proportion of apoptotic cells. Transmission electron microscopy (TEM) To visualize cellular ultrastructure, cells were initially fixed in 2.5% glutaraldehyde for 8 h, followed by washing with phosphate buffer saline (PBS). Post-fixation was carried out using 1% OsO4 for 2 h. The specimens were then dehydrated through a graded ethanol series and infiltrated with a 1:1 mixture of acetone and Epon 812 resin. Then ultrathin sections with approximately 60–80 nm in thickness were prepared using an ultramicrotome. These sections were placed onto nickel grids coated with formvar film and subjected to staining with 2% uranyl acetate followed by lead citrate. Imaging was performed using a HT7700-SS transmission electron microscope (Hitachi, Japan). mRFP-GFP-LC3 puncta assay H9C2 cells were infected with the recombinant adenovirus Ad-mRFP-GFP-LC3 (GeneChem, Shanghai, China) at a multiplicity of infection (MOI) of 50. After treatment with OGD and finerenone, cells were fixed with 4% paraformaldehyde (PFA) and stained with DAPI to visualize nuclei. Fluorescent signals were captured using a confocal microscope (TCS SP8, Leica, Germany). Autophagic flux was evaluated by quantifying the number of intracellular LC3 puncta exhibiting green (GFP) and red (mRFP) fluorescence. Vasculogenic mimicry assay After treatment, HUVECs were seeded at a density of 1 × 10⁵ cells per well onto 24-well plates that had been pre-coated with 200 µL Matrigel matrix (Corning, USA). Cells were incubated overnight at 37 °C to allow the formation of tubular networks. The resulting structures were visualized using an inverted microscope (IX71, OLYMPUS, Japan). Quantitative assessment of tube formation (100×) was performed using Image-Pro Plus 6.0 software. Three wells were selected randomly from each group. Wound healing assay for HUVECs HUVECs were cultured in 3.5-cm dishes until reaching approximately 90% confluency. A linear scratch was gently generated across the cell monolayer using a sterile pipette tip of 200 µL to simulate a wound gap. Detached cells and debris were carefully removed by rinsing with PBS. Subsequently, cells were subjected to OGD and finerenone. Phase-contrast images were captured at 0 and 48 h using an inverted microscope at 100× magnification. The remaining wound area was quantified using ImageJ software. Each experiment was conducted in triplicate. MI induction and finerenone treatment MI was induced through permanent ligation of the left anterior descending (LAD) coronary artery, following a modified procedure referenced in previous studies17. In brief, mice were anesthetized using 3% isoflurane and ventilated mechanically with a small-animal respirator. A left thoracotomy was performed between the third and fifth intercostal spaces to expose the left atrium and ventricle. Under a stereomicroscope, the LAD was permanently ligated approximately 2–3 mm below the left atrial appendage using a 6 − 0 sterile suture. Mice in the sham group underwent an identical surgical procedure, except that the suture was passed beneath the LAD without tying the knot. Successful occlusion was confirmed by visual pallor of the anterior ventricular wall and regional dyskinesia. Following the procedure, the chest cavity was closed in layers. Finerenone was administered via daily oral gavage at a dosage of 10 mg/kg/day to MI mice from the day of surgery until postoperative day 28, while sham control and MI control mice received equivalent volumes of sterile saline. TTC staining was performed on samples harvested 2 days after surgery, and other specimens were collected 28 days postoperatively for subsequent analyses. TTC staining Ten hearts were collected from each group and stored at -20 °C overnight. The frozen hearts were taken out, and under frozen conditions, the hearts were uniformly and continuously sectioned along the long axis of the left ventricle using a pre-cooled sharp blade. Then, the cut heart slices were placed in TTC staining solution (Jiancheng Bioengineering Institute, China) and incubated at 37 °C for 15 min. After incubation, the myocardial slices were taken out, rinsed briefly with PBS, arranged neatly, and fixed in 4% formaldehyde solution. The stained myocardial slices exhibited two distinct colors: red indicating viable normal myocardial tissue and pale white representing necrotic infarcted tissue. Images of the stained slices were captured, and infarct size was quantified using ImageJ software by measuring the areas of viable red myocardium and pale white infarcted tissue. The percentage of infarct area relative to the total ventricular area was subsequently calculated to assess the degree of MI. Histological assessment On day 28, mice were sacrificed. Hearts were promptly excised, and then embedded in OCT compound and snap-frozen. Serial paraffin sections of 5-µm thickness were prepared at 500-µm intervals. Hematoxylin and eosin (H&E) staining was utilized to examine myocardial cellular morphology within the infarct region, while Masson’s trichrome staining was applied to evaluate the extent of fibrotic remodeling. Histological sections were analyzed under microscopy, with collagen deposition appearing as blue-stained areas indicative of fibrosis. Apoptotic cell death was evaluated by TUNEL staining. Briefly, 5-µm paraffin sections were deparaffinized with xylene and rehydrated through a graded ethanol series. Then membrane permeabilization was performed with 0.1% Triton X-100. Paraffin sections were then incubated with the TUNEL reaction mixture at ambient temperature for 60 min. Nuclei were subsequently counterstained with DAPI. Fluorescent images were acquired using a fluorescence microscope, and apoptotic index was calculated as the proportion of TUNEL-positive nuclei relative to the total number of cardiomyocyte nuclei. During immunohistochemical analysis, paraffin-embedded myocardial sections were initially deparaffinized using xylene and subsequently rehydrated through a graded ethanol series. Heat-mediated antigen retrieval was carried out in a citrate buffer solution. The tissue sections were then incubated overnight at 4 °C with primary antibodies against angiopoietin, autophagy related 5, collagen type I alpha 1 chain, and vascular endothelial growth factor. HRP-conjugated secondary antibodies were applied for signal development using 3,3′-diaminobenzidine as the chromogenic substrate. The slides were counterstained with hematoxylin to visualize nuclei. Digital images were captured under a microscope, and accumulated optical density was quantified using ImageJ software. Echocardiography, electrocardiogram and biochemical analysis of myocardial enzymes Transthoracic echocardiographic assessments were conducted in mice anesthetized with 1–2% isoflurane using a high-resolution imaging platform (Vevo2100, VisualSonics, canada). Electrocardiogram signals and cardiac rhythm were continuously recorded. Two-dimensional short-axis views of the left ventricle were obtained to quantify the internal diameter at end-systole (LVIDs) and end-diastole (LVIDd), along with posterior wall thickness during both systole (LVPWs) and diastole (LVPWd). Subsequently, the probe was repositioned to acquire apical four-chamber views, from which early (E) and late (A) diastolic transmitral flow velocities were measured. The myocardial enzyme profile comprised aspartate aminotransferase (AST), creatine kinase (CK), creatine kinase-MB isoenzyme (CK-MB), lactate dehydrogenase (LDH), and α-hydroxybutyrate dehydrogenase (α-HBDH). Quantitative measurements were performed employing commercially available assay kits. Brain natriuretic peptide (BNP) concentrations were determined by enzyme-linked immunosorbent assay. Western blot analysis Myocardial tissue samples were homogenized in a lysis buffer supplemented with 1% phenylmethylsulfonyl fluoride. Following centrifugation, the supernatants were collected as total protein extracts. The protein concentration was determined using a BCA protein assay. 30 µg protein per sample was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently transferred onto polyvinylidene fluoride membranes. Membranes were blocked at ambient temperature with 5% non-fat dry milk for 2 h. Thereafter, membranes were incubated overnight at 4 °C with the following primary antibodies: anti-Bcl-2 (1:1000, Cell Signaling Technology, USA), anti-BAX (1:1000, CST), anti-Caspase-3 (1:1000, CST), anti-Caspase-9 (1:1000, CST), anti-PARP (1:1000, CST), anti-Fas (1:1000, CST), anti-FasL (1:1000, CST), anti-TNF (1:1000, CST), anti-TNFR (1:1000, CST), and anti-GAPDH (1:1000, CST). Then, they were washed and probed with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000) for 1 h at 25 °C. Immunoreactive bands were visualized using enhanced chemiluminescence (ECL) detection reagents. The signal intensities were quantified by densitometric analysis, and expression levels of target proteins were normalized to GAPDH. Notably, the infarcted tissue from the anterior wall of the left ventricle was manually dissected and collected under microscopic for subsequent protein extraction and quantitative detection. Statistical analysis All statistical analyses were performed using SPSS 18.0 or GraphPad Prism 11.0. Data were shown as mean ± standard deviation (SD). For three group comparisons, one-way analysis of variance was employed, followed by Bonferroni adjustment. For comparisons between two groups, the student’s t-test was employed. A p-value less than 0.05 was considered indicative of statistical significance. Results Attenuation of autophagic vacuoles and apoptotic nuclear condensation in OGD-Injured H9C2 cardiomyocytes by finerenone Compared to the control group, treatment with finerenone ranging from 1 µM to 500 µM exerted no significant effects on cell viability. However, at concentrations from 1 mM to 8 mM, cell viability decreased significantly in a dose-dependent manner (Fig. 1A). Compared with the OGD group, the OGD + 500 µM finerenone group exhibited significantly increased cell survival rates at 1, 2, 3, and 6 h of post-treatment (Fig. 1B). Therefore, subsequent experiments selected 500 µM finerenone for 6 h as the optimal intervention condition. TEM revealed that cells in the OGD group showed pronounced vacuolization, disrupted organelle ultrastructure, chromatin condensation, decreased mitochondrial number accompanied by swelling, and increased autophagosomes. Following finerenone intervention, cellular structural damage was alleviated, autophagosome numbers were reduced, and nuclear contours remained clearly delineated (Fig. 1C). Fig. 1Finerenone inhibits autophagy and apoptosis in H9C2 cells. (A) Cell viability of H9C2 cells induced by finerenone after 24 h by CCK-8 assay. (B) Finerenone improved the cell viability of OGD-insulted H9C2 cells. (C) Organelle morphological changes were observed using transmission electron microscopy (TEM) in OGD-insulted H9C2 cells exposed to finerenone for 6-h post-treatment. Bar = 1 μm. ***p < 0.001 compared with control group; ###p < 0.001 compared with the OGD group. Finerenone inhibits autophagy and apoptosis in H9C2 cells. (A) Cell viability of H9C2 cells induced by finerenone after 24 h by CCK-8 assay. (B) Finerenone improved the cell viability of OGD-insulted H9C2 cells. (C) Organelle morphological changes were observed using transmission electron microscopy (TEM) in OGD-insulted H9C2 cells exposed to finerenone for 6-h post-treatment. Bar = 1 μm. ***p < 0.001 compared with control group; ###p < 0.001 compared with the OGD group. Effects of finerenone on autophagy and apoptosis Given the reduction of autophagic vacuole formation observed by TEM, autophagic flux was assessed using the Ad-mRFP-GFP-LC3 tandem fluorescent reporter system. Finerenone treatment increased the number of GFP⁺RFP⁺ yellow puncta without increasing RFP⁺ red puncta, suggesting that finerenone inhibited autophagic flux under OGD-induced injury (Fig. 2A). Western blot analysis of LC3 isoforms revealed enhanced conversion of LC3-I to LC3-II in the OGD group, with elevated p62 and ATG5 expressions relative to the finerenone group, indicating that finerenone alleviated OGD-induced autophagic impairment and reduced autophagosome accumulation (Fig. 2B; Original blots are presented in Supplementary Fig. 1). Additionally, finerenone markedly decreased OGD-induced damage in H9C2 cells and apoptosis rates (Fig. 3A, B). Compared with the OGD group, finerenone treatment downregulated the pro-apoptotic protein Bax, but upregulated the anti-apoptotic protein BCL2 and the BCL2/Bax ratio. Concurrently, the expression of extrinsic apoptotic pathway-associated molecules, including Fas, FasL, TNF-α, and the caspase-3 substrate PARP, were also significantly reduced (Fig. 3C; Original blots are presented in Supplementary Fig. 2). Fig. 2Autophagy flux is blocked by finerenone. (A) H9C2 cells were infected with the Ad-mRFP-GFP-LC3. Then, the cells were treated with OGD injury and finerenone and observed by confocal microscope. The histograms showed the quantification of green and red puncta, which was performed using ImageJ software. Yellow puncta (GFP⁺RFP⁺) indicated non-fused autophagosomes, whereas red puncta (RFP⁺) represented total autophagic structures including autolysosomes. (B) Cells were treated with OGD injury and finerenone, and the levels of LC3-I, LC3-II, p62 and ATG5 were detected by Western blotting. Bar = 20 μm. **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with OGD + PBS group. Autophagy flux is blocked by finerenone. (A) H9C2 cells were infected with the Ad-mRFP-GFP-LC3. Then, the cells were treated with OGD injury and finerenone and observed by confocal microscope. The histograms showed the quantification of green and red puncta, which was performed using ImageJ software. Yellow puncta (GFP⁺RFP⁺) indicated non-fused autophagosomes, whereas red puncta (RFP⁺) represented total autophagic structures including autolysosomes. (B) Cells were treated with OGD injury and finerenone, and the levels of LC3-I, LC3-II, p62 and ATG5 were detected by Western blotting. Bar = 20 μm. **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with OGD + PBS group. Fig. 3Apoptosis is blocked by finerenone. (A) 500 µM finerenone reduced the LDH release of OGD/R-insulted H9C2 cells. (B) Finerenone suppressed the apoptosis rate of OGD/R-insulted H9C2 cell as measured by Annexin V staining and flow cytometry analysis. (C) Finerenone protected OGD/R-insulted H9C2 cells, and the levels of Bax, BCL2, Fas, FasL, TNF-α and PARP were detected by Western blotting. ***p < 0.001, ****p < 0.0001 compared with OGD + PBS group. Apoptosis is blocked by finerenone. (A) 500 µM finerenone reduced the LDH release of OGD/R-insulted H9C2 cells. (B) Finerenone suppressed the apoptosis rate of OGD/R-insulted H9C2 cell as measured by Annexin V staining and flow cytometry analysis. (C) Finerenone protected OGD/R-insulted H9C2 cells, and the levels of Bax, BCL2, Fas, FasL, TNF-α and PARP were detected by Western blotting. ***p < 0.001, ****p < 0.0001 compared with OGD + PBS group. In vitro and in vivo protective effects of finerenone To further validate the integrative protective effect of finerenone, experiments were further conducted in HUVECs (Fig. 4). Compared with the control group, OGD treatment significantly reduced the cell viability, migratory capacity, and angiogenic potential. However, intervention with 500 µM finerenone significantly enhanced cell viability and migration relative to the OGD group, with a concomitant increase in the number of capillary-like structures formed on Matrigel. Regarding the cardioprotective effects in vivo, electrocardiogram analysis demonstrated that elevated ST segments in the MI group were significantly higher than those in the Sham group, whereas finerenone treatment markedly normalized ST segments towards baseline levels (Fig. 5A). Compared with the MI group, finerenone significantly reduced serum myocardial enzyme levels, including AST, CK, CK-MB, LDH, and α-HBDH, alongside a significant decrease in the BNP (Fig. 5B). Echocardiographic assessment revealed improvements in the left ventricular structure and function, evidenced by significant decreases in LVIDs, LVIDd, and E/A ratio, but increases in LVPWd and LVPWs following finerenone treatment (Fig. 5C). At 28 days post-MI, TTC staining results showed that compared with the Sham group, the infarct area in the MI group was significantly increased, and the administration of finerenone could effectively reverse this effect (Fig. 5D). Histopathological analysis demonstrated intact myocardial architecture, orderly cell arrangement, and clear boundaries with minimal collagen deposition and TUNEL-positive cells in the Sham group. Conversely, the MI group exhibited myofibrillar disarray, pronounced inflammation, fibrosis, and increased apoptosis. Finerenone treatment effectively suppressed inflammatory infiltration, preserved myocardial architecture, reduced fibrosis area and apoptosis (Fig. 5E and F). Fig. 4Finerenone improves angiogenesis in vitro. (A) 500 µM finerenone improved the cell viability of OGD-insulted HUVECs. (B) Representative results of cell motility assessed by scratch wound-healing assay. The upper group of images represents the wound at zero time of treatment while lower images represent the wound after 48 h of finerenone treatment on OGD-insulted HUVECs. (C) Capillary-like tubular structures promoted by finerenone by vasculogenic mimicry assay. Magnification was 100×. **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with control group; ###p < 0.001, ####p < 0.0001 compared with OGD group. Finerenone improves angiogenesis in vitro. (A) 500 µM finerenone improved the cell viability of OGD-insulted HUVECs. (B) Representative results of cell motility assessed by scratch wound-healing assay. The upper group of images represents the wound at zero time of treatment while lower images represent the wound after 48 h of finerenone treatment on OGD-insulted HUVECs. (C) Capillary-like tubular structures promoted by finerenone by vasculogenic mimicry assay. Magnification was 100×. **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with control group; ###p < 0.001, ####p < 0.0001 compared with OGD group. Fig. 5In Vivo cardioprotective effects of finerenone. (A) Impacts on electrocardiograms of mice at 28 days post-surgery in Sham, MI and MI + finerenone groups. (B) Serum parameters of AST, CK, CK-MB, LDH, α-HBDH and BNP in mice. (C) Finerenone improved the cardiac function by echocardiography, including reduction of E/A ratio, LVIDs, LVIDd and preservation of LVPWd and LVPWs. (D) Representative TTC staining results of the heart tissue in short-axis sections from the cardiac apex to base among the three groups. (E) Representative H&E and Masson-stained heart sections for the groups. (F) The apoptosis of cardiomyocytes was determined by TUNEL staining. Quantitative analysis of cardiomyocyte apoptosis. ****p < 0.0001 compared with sham group; ####p < 0.0001 compared with the model (MI) group. In Vivo cardioprotective effects of finerenone. (A) Impacts on electrocardiograms of mice at 28 days post-surgery in Sham, MI and MI + finerenone groups. (B) Serum parameters of AST, CK, CK-MB, LDH, α-HBDH and BNP in mice. (C) Finerenone improved the cardiac function by echocardiography, including reduction of E/A ratio, LVIDs, LVIDd and preservation of LVPWd and LVPWs. (D) Representative TTC staining results of the heart tissue in short-axis sections from the cardiac apex to base among the three groups. (E) Representative H&E and Masson-stained heart sections for the groups. (F) The apoptosis of cardiomyocytes was determined by TUNEL staining. Quantitative analysis of cardiomyocyte apoptosis. ****p < 0.0001 compared with sham group; ####p < 0.0001 compared with the model (MI) group. Effects of finerenone on the cell signaling in infarcted hearts Immunohistochemistry showed weak and dispersed ATG5 expression in the Sham group, markedly increased and widely distributed expression in the MI group, but significantly reduced expression following finerenone treatment (Fig. 6A). Western blot analysis further revealed upregulated pro-apoptotic Bax and downregulated anti-apoptotic BCL2 in the MI group. Components of the caspase cascade, including initiator caspase-9, effector caspase-3, and substrate PARP, were significantly elevated, alongside enhanced expressions of extrinsic apoptotic pathway molecules Fas, FasL, and TNF-α, indicating pronounced apoptosis in the MI tissue. Finerenone treatment could significantly inhibit these apoptotic processes (Fig. 6B; Original blots are presented in Supplementary Fig. 3). Regarding angiogenesis, Ang and VEGF expressions were elevated in the MI group compared with the Sham group, with finerenone intervention further augmenting their expressions (Fig. 6C). Fig. 6Finerenone inhibits autophagy, apoptosis, and enhances angiogenesis in attenuating myocardial injury. (A) Representative immunohistochemical staining images for ATG5 among the three treatment groups after MI. Quantitative analysis of average optical density from the images. (B) Western blotting was performed to detect Bax, BCL2, caspase-9, caspase-3, PARP, Fas, FasL, and TNF-α of myocardial tissue. Total proteins and GAPDH were used as loading control. (C) Representative immunohistochemical staining images for Ang, Col1A1, VEGF for the groups. ****p < 0.0001 compared with sham group; ####p < 0.0001 compared with model group. Finerenone inhibits autophagy, apoptosis, and enhances angiogenesis in attenuating myocardial injury. (A) Representative immunohistochemical staining images for ATG5 among the three treatment groups after MI. Quantitative analysis of average optical density from the images. (B) Western blotting was performed to detect Bax, BCL2, caspase-9, caspase-3, PARP, Fas, FasL, and TNF-α of myocardial tissue. Total proteins and GAPDH were used as loading control. (C) Representative immunohistochemical staining images for Ang, Col1A1, VEGF for the groups. ****p < 0.0001 compared with sham group; ####p < 0.0001 compared with model group. Discussion This study investigated finerenone’s cardioprotective effects and mechanisms post-MI in vivo and in vitro. We demonstrated that finerenone preserved cardiac structural integrity and improved cardiac function in a murine MI model. 28-day administration of finerenone ameliorated ST-segment changes, reduced serum myocardial enzymes and BNP, diminished infarct size, and enhanced left ventricular function. Histopathology showed relieved myofibrillar disarray, inflammatory infiltration, fibrosis and cardiomyocyte apoptosis. Furthermore, finerenone also modulated myocardial autophagy-, apoptosis- and angiogenesis-related molecular markers within myocardial tissue. These findings all suggest that finerenone confers cardioprotection through multi-level preservation of cardiomyocytes and vascular endothelial cells, thereby partially restoring the structure and function in the post-infarct heart. In OGD-injured H9C2 cardiomyocytes, we observed that finerenone could alleviate OGD-induced cellular structural damage, including reducing vacuolization, preserving organelle ultrastructure, and mitigating chromatin condensation and mitochondrial swelling. These findings provide direct evidence that finerenone exerts a direct cytoprotective effect on cardiomyocytes under ischemic stress, which extends beyond its previously reported effects on non-cardiomyocyte populations18,19. Autophagy is a double-edged sword in MI. Moderate autophagy can protect cardiomyocytes by removing damaged organelles and maintaining cellular homeostasis, while excessive or impaired autophagy can exacerbate cell injury and death. Our study demonstrated that OGD-induced injury led to increased autophagosome accumulation and impaired autophagic flux in H9C2 cells, as evidenced by enhanced conversion of LC3-I to LC3-II, elevated p62 and ATG5 expression, and changes in the distribution of GFP⁺RFP⁺ puncta. Finerenone treatment significantly alleviated these autophagic abnormalities, suggesting that its cardioprotective effect is partially mediated by restoring normal autophagic function. This is consistent with previous studies showing that MR activation can disrupt autophagic flux and promote excessive autophagy, while MR antagonism can reverse these effects20. Notably, however, the lack of assessment of autophagic flux markers LC3-I, LC3-II, and p62 at 28 days after permanent LAD ligation limited the full interpretation of the precise autophagic mechanisms underlying finerenone’s cardioprotection, which may be due to the focus of our study on long-term functional outcomes post-MI. In the future, we will incorporate these key autophagic markers to strengthen the mechanistic evidence underlying finerenone’s cardioprotective effects. Apoptosis of cardiomyocytes is a major contributor to the irreversible loss of myocardial tissue following MI, and inhibiting cardiomyocyte apoptosis is a key therapeutic strategy for improving post-MI prognosis21. Our results showed that finerenone significantly reduced OGD-induced apoptosis in H9C2 cells, as indicated by decreased apoptotic rates and expression of apoptotic pathway-associated molecules, which were further validated in vivo, namely finerenone treatment significantly reduced TUNEL-positive apoptotic cells in the infarcted myocardium and inhibited the upregulation of pro-apoptotic molecules and activation of the caspase cascade induced by MI. Collectively, these results indicate that finerenone exerts anti-apoptotic effects through both intrinsic and extrinsic pathways, which contributes to the preservation of cardiomyocyte viability and reduction of infarct size. Post-MI endothelial injury disrupts vascular homeostasis, subsequently impacting inflammation, myocardial repair, and cardiac remodeling. Although prior studies suggested that finerenone improved endothelial function in MI22–24, direct evidence targeting endothelial cells remained limited. Our results demonstrated that finerenone significantly enhanced the survival, migration, and tube formation capacities of HUVECs under OGD conditions. In vivo, finerenone upregulated the expression of angiogenic factors Ang and VEGF, indicating its potential to promote angiogenesis. Additionally, finerenone reduced myocardial collagen deposition, inhibited fibrotic progression, and lowered serum BNP levels. As the key pro-angiogenic mediators, Ang and VEGF are upregulated in ischemic tissue to promote neovascularization and endothelial repair, thereby improving local perfusion25. Endothelial dysfunction can activate inflammation and fibroblast proliferation, increase collagen deposition and precipitate myocardial fibrosis, which ultimately impairs cardiac compliance and contractility26,27. Collectively, finerenone can effectively restore endothelial function and facilitate neovascularization. In our study of a murine MI model, finerenone’s cardioprotective effects were further confirmed. Treatment with finerenone normalized ST-segment elevation, reduced serum myocardial enzymes and BNP, and effectively diminished infarct size at 28 days post-MI, with improvements in left ventricular function. These in vivo findings align with in vitro results, highlighting finerenone’s multi-level cardioprotection. Notably, infarct size is the primary determinant of cardiac function and remodeling28. In our study, the observed improvements in cardiac function and molecular changes were highly likely to be closely associated with the reduction in infarct size, aligning with the classic pathophysiological cascade of cardiac remodeling “intervention-reduction of initial injury/slowing of injury progression-improvement of long-term cardiac structure and function”. These cardiac functional benefits we identified are most probably a secondary consequence of diminished infarct size, a key manifestation of finerenone’s cardioprotective effects. This study has several limitations that should be acknowledged. First, we utilized an OGD model rather than the more physiologically relevant hypoxia/reoxygenation model to simulate I/R injury. While the OGD model is well-established for studying ischemic stress and initial screening, it does not fully recapitulate the complex cascade of events during reperfusion, such as the burst of reactive oxygen species and calcium overload, which are critical in clinical I/R injury. Future investigations employing hypoxia/reoxygenation protocols are warranted to confirm our findings in a model that more closely mimics the clinical scenario. Second, the experiments were conducted using a rat cardiomyoblast cell line. This choice was primarily based on practical considerations, including ease of culture, high reproducibility, and suitability for high-throughput screening. However, it is important to note that these cells, while expressing some cardiac markers, differ from adult primary cardiomyocytes in terms of their metabolic profile, contractile apparatus, and electrophysiological properties. Therefore, the extrapolation of our results to mature cardiac muscle requires caution, and validation in primary cardiomyocytes or in vivo models is essential for future work. Third, regarding the endpoints for assessing cardioprotection, we employed a panel of complementary assays to gauge acute injury. We recognize, in alignment with established guidelines in the field, that infarct size remains the most robust and clinically translatable primary endpoint for evaluating protective efficacy. Although our multi-parametric approach provides mechanistic insights, subsequent studies should prioritize infarct size measurement as the definitive outcome in validated experimental models of I/R injury. Furthermore, a significant limitation of this study lies in the use of a permanent occlusion model to induce myocardial ischemia. While this model provides a stable and reproducible experimental setting to investigate the effects of interventions during the ischemic phase, it does not reflect the contemporary clinical reality for patients with acute coronary syndrome. In clinical practice, rapid reperfusion via PCI or thrombolysis is the standard of care. Consequently, the permanent occlusion model fails to capture the complex and often detrimental biological processes of reperfusion injury, such as the abrupt generation of reactive oxygen species, calcium overload, and intense inflammatory responses, which are critical determinants of final infarct size. As highlighted in the practical guidelines on cardioprorection29, the ischemic damage followed by reperfusion is pathophysiologically distinct from damage due to ischemia alone. Therefore, the therapeutic efficacy observed in our permanent occlusion model requires cautious interpretation and must be validated in established I/R models to better assess its potential clinical translatability. Conclusion Finerenone confers significant cardioprotection by inhibiting autophagy, apoptosis, and enhancing angiogenesis in both cardiomyocytes and vascular endothelial cells. These findings provide experimental evidence for the clinical utility of finerenone for secondary prevention after MI. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1